The global biologic therapeutics drugs market was valued at USD 469.7 billion in 2023, growing at a CAGR of 12.2% from 2024 to 2033. The market is expected to reach USD 1485.0 billion by 2033. The market for biologic therapeutic drugs is expected to develop due to several factors, including an increase in the ageing population and the incidence of chronic illnesses like diabetes, cancer, and coronary artery disease.
Genetically modified proteins obtained from human DNA make up biological therapies. They may be living things like cells and tissues or contain complicated mixtures of various components, such as carbohydrates, proteins, and nucleic acids. Furthermore, biologics medications come from naturally occurring sources like humans, animals, and microorganisms, which are then used to create vaccines, blood components, and recombinant therapeutic proteins, among other therapeutic goods. The need for advanced diagnostics and treatment drugs has increased due to the prevalence and diagnosis of chronic illnesses, which has propelled the global biologic therapeutic drugs market. Genetically engineered medications known as biologics are designed to target an immune system component that triggers inflammation specifically. Furthermore, many clinical studies and cutting-edge R&D strategies to create cutting-edge medications fuel market expansion. The ability of biologics to treat severe infections, cancer, autoimmune diseases, and hormonal imbalances motivates pharmaceutical companies to spend money on research and development to create new biologics. One of the biological therapy areas that is expanding the fastest is monoclonal antibodies.
Get an overview of this study by requesting a free sample
In June 2022, Administrators refused to apply Aeglea BioTherapuetics' biologic pegzilarginase, and the business subsequently declared that it had not been successful in obtaining a biologics licence application (BLA) from the FDA.
In February 2022, The US Food and Drug Administration (FDA) approved CARVYKTI (ciltacabtagene autoleucel; cilia-cel) for use by Janssen Pharmaceutical Companies of Johnson & Johnson. Adults with relapsed or refractory multiple myeloma (RRMM) who have not responded to four or more previous lines of therapy—including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies—are treated with this biologic medication.
Development of drugs for arthritis—The medical sector highly values the creation of novel drugs and treatments. Since rheumatoid arthritis is one of the chronic conditions expanding the fastest in the business, drugs for treating it have attracted a lot of interest. A doctor determined that an estimated 78.4 million adults will have arthritis by 2040.
High development cost- Since the creation of biologics requires a significant financial investment and takes a long period, developers and producers of biologics confront difficulties. Years may pass between the first investment and the market's acceptance. Due to the need for ongoing clinical studies, research-based activities, and manufacturing procedures, this extended schedule raises overall expenses. This element may discourage producers from entering the market, impeding its expansion. Hence, it is seen as a market constraint.
Rising demand for personalized medicine- Personalised medicine frequently relies on targeted medicines intended to target certain molecular targets within the human body. Biomarker identification plays a major role in personalised medicine. Biomarkers and other diagnostic tools are developed largely owing to biologics. This may aid in the diagnosis of illnesses. The field of personalised medicine is witnessing a surge in demand for therapies tailored to each patient's unique needs. Treatment alternatives that are more patient-centred and successful can be achieved by modifying and engineering biologics to meet these objectives. Thus, the industry is opening up due to the desire for personalised treatment.
The regions analyzed for the market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. North America emerged as the largest global biologic therapeutics drugs market region, with a 39.8% market revenue share in 2023.
This can be attributed to several things, such as the high rate of chronic illnesses, several top biopharmaceutical businesses, advantageous reimbursement guidelines, and substantial R&D expenditures. According to a JAMA Network report, 37% of all U.S. medication spending was allocated to biologics. Some of the factors driving the market expansion include the rising percentage of prescriptions for biologics and the rising amount of money invested in creating targeted medications. Additionally, approving other innovative biologic medications, including gene therapy, antisense, and RNAi treatments, is anticipated to spur future market expansion.
North America Region Biologic Therapeutics Drugs Market Share in 2023 - 39.8%
www.thebrainyinsights.com
Check the geographical analysis of this market by requesting a free sample
The product segment is divided into vaccines, cellular-based biologics, monoclonal antibodies, recombinant hormones/proteins, gene-based biologics and others. The monoclonal antibodies segment dominated the market, with a market share of around 25% in 2023. As monoclonal antibodies are used in many therapeutic fields, their rising utilisation has led to a dominant market share. Monoclonal antibodies make it possible to target ill cells without endangering healthy cells.
The application segment is divided into autoimmune diseases, infectious diseases, cancer, and others. The cancer segment dominated the market, with a market share of around 34% in 2023. Increase in incidences of cancer of and rise in number of people suffering from cancer is expected to increase the demand for biologic therapeutics drugs.
Report Description:
Attribute | Description |
---|---|
Market Size | Revenue (USD Billion) |
Market size value in 2023 | USD 469.7 Billion |
Market size value in 2033 | USD 1485.0 Billion |
CAGR (2024 to 2033) | 12.2% |
Historical data | 2020-2022 |
Base Year | 2023 |
Forecast | 2024-2033 |
Region | The regions analyzed for the market are Asia Pacific, Europe, South America, North America, and Middle East & Africa. Furthermore, the regions are further analyzed at the country level. |
Segments | Product, Application |
As per The Brainy Insights, the size of the biologic therapeutics drugs market was valued at USD 469.7 billion in 2023 to USD 1485.0 billion by 2033.
The global biologic therapeutics drugs market is growing at a CAGR of 12.2% during the forecast period 2024-2033.
North America emerged as the largest biologic therapeutics drugs market.
Key players in the biologic therapeutics drugs market are Amgen Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Bayer AG, Novartis AG, AbbVie Inc., Eli Lilly and Company, GlaxoSmithKline PLC, Merck & Co., Sanofi SA, and AstraZeneca PLC.
This study forecasts global, regional, and country revenue from 2020 to 2033. The Brainy Insights has segmented the global biologic therapeutics drugs market based on the below-mentioned segments:
Global Biologic Therapeutics Drugs Market By Product:
Global Biologic Therapeutics Drugs Market By Application:
Global Biologic Therapeutics Drugs Market By Region:
Research has its special purpose to undertake marketing efficiently. In this competitive scenario, businesses need information across all industry verticals; the information about customer wants, market demand, competition, industry trends, distribution channels etc. This information needs to be updated regularly because businesses operate in a dynamic environment. Our organization, The Brainy Insights incorporates scientific and systematic research procedures in order to get proper market insights and industry analysis for overall business success. The analysis consists of studying the market from a miniscule level wherein we implement statistical tools which helps us in examining the data with accuracy and precision.
Our research reports feature both; quantitative and qualitative aspects for any market. Qualitative information for any market research process are fundamental because they reveal the customer needs and wants, usage and consumption for any product/service related to a specific industry. This in turn aids the marketers/investors in knowing certain perceptions of the customers. Qualitative research can enlighten about the different product concepts and designs along with unique service offering that in turn, helps define marketing problems and generate opportunities. On the other hand, quantitative research engages with the data collection process through interviews, e-mail interactions, surveys and pilot studies. Quantitative aspects for the market research are useful to validate the hypotheses generated during qualitative research method, explore empirical patterns in the data with the help of statistical tools, and finally make the market estimations.
The Brainy Insights offers comprehensive research and analysis, based on a wide assortment of factual insights gained through interviews with CXOs and global experts and secondary data from reliable sources. Our analysts and industry specialist assume vital roles in building up statistical tools and analysis models, which are used to analyse the data and arrive at accurate insights with exceedingly informative research discoveries. The data provided by our organization have proven precious to a diverse range of companies, facilitating them to address issues such as determining which products/services are the most appealing, whether or not customers use the product in the manner anticipated, the purchasing intentions of the market and many others.
Our research methodology encompasses an idyllic combination of primary and secondary initiatives. Key phases involved in this process are listed below:
The phase involves the gathering and collecting of market data and its related information with the help of different sources & research procedures.
The data procurement stage involves in data gathering and collecting through various data sources.
This stage involves in extensive research. These data sources includes:
Purchased Database: Purchased databases play a crucial role in estimating the market sizes irrespective of the domain. Our purchased database includes:
Primary Research: The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. Primary research mainly involves in telephonic interviews, E-mail interactions and face-to-face interviews with the raw material providers, manufacturers/producers, distributors, & independent consultants. The interviews that we conduct provides valuable data on market size and industry growth trends prevailing in the market. Our organization also conducts surveys with the various industry experts in order to gain overall insights of the industry/market. For instance, in healthcare industry we conduct surveys with the pharmacists, doctors, surgeons and nurses in order to gain insights and key information of a medical product/device/equipment which the customers are going to usage. Surveys are conducted in the form of questionnaire designed by our own analyst team. Surveys plays an important role in primary research because surveys helps us to identify the key target audiences of the market. Additionally, surveys helps to identify the key target audience engaged with the market. Our survey team conducts the survey by targeting the key audience, thus gaining insights from them. Based on the perspectives of the customers, this information is utilized to formulate market strategies. Moreover, market surveys helps us to understand the current competitive situation of the industry. To be precise, our survey process typically involve with the 360 analysis of the market. This analytical process begins by identifying the prospective customers for a product or service related to the market/industry to obtain data on how a product/service could fit into customers’ lives.
Secondary Research: The secondary data sources includes information published by the on-profit organizations such as World bank, WHO, company fillings, investor presentations, annual reports, national government documents, statistical databases, blogs, articles, white papers and others. From the annual report, we analyse a company’s revenue to understand the key segment and market share of that organization in a particular region. We analyse the company websites and adopt the product mapping technique which is important for deriving the segment revenue. In the product mapping method, we select and categorize the products offered by the companies catering to domain specific market, deduce the product revenue for each of the companies so as to get overall estimation of the market size. We also source data and analyses trends based on information received from supply side and demand side intermediaries in the value chain. The supply side denotes the data gathered from supplier, distributor, wholesaler and the demand side illustrates the data gathered from the end customers for respective market domain.
The supply side for a domain specific market is analysed by:
The demand side for the market is estimated through:
In-house Library: Apart from these third-party sources, we have our in-house library of qualitative and quantitative information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, historic databases, internal audit reports and archives.
Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those cases, we use our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopt a robust research technique in order to produce the estimates:
Data Synthesis: This stage involves the analysis & mapping of all the information obtained from the previous step. It also involves in scrutinizing the data for any discrepancy observed while data gathering related to the market. The data is collected with consideration to the heterogeneity of sources. Robust scientific techniques are in place for synthesizing disparate data sets and provide the essential contextual information that can orient market strategies. The Brainy Insights has extensive experience in data synthesis where the data passes through various stages:
Market Deduction & Formulation: The final stage comprises of assigning data points at appropriate market spaces so as to deduce feasible conclusions. Analyst perspective & subject matter expert based holistic form of market sizing coupled with industry analysis also plays a crucial role in this stage.
This stage involves in finalization of the market size and numbers that we have collected from data integration step. With data interpolation, it is made sure that there is no gap in the market data. Successful trend analysis is done by our analysts using extrapolation techniques, which provide the best possible forecasts for the market.
Data Validation & Market Feedback: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helps us finalize data-points to be used for final calculations.
The Brainy Insights interacts with leading companies and experts of the concerned domain to develop the analyst team’s market understanding and expertise. It improves and substantiates every single data presented in the market reports. The data validation interview and discussion panels are typically composed of the most experienced industry members. The participants include, however, are not limited to:
Moreover, we always validate our data and findings through primary respondents from all the major regions we are working on.
Free Customization
Fortune 500 Clients
Free Yearly Update On Purchase Of Multi/Corporate License
Companies Served Till Date